[144] Lineage Cell Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Lineage Cell Therapeutics (LCTX) notice records a proposed sale of 80,000 common shares under Rule 144, with an aggregate market value of $97,472. The shares are listed on the NYSE and were acquired and are proposed to be sold on 09/10/2025 following a stock option exercise paid in cash. The filing names Morgan Stanley Smith Barney LLC Executive Financial Services as the broker for the transaction and shows 228,356,290 shares outstanding, with no other sales by the filer in the past three months reported. The filer certifies no undisclosed material adverse information regarding the issuer.

Positive

• Transaction disclosed under Rule 144, showing regulatory compliance
• Brokered through Morgan Stanley Smith Barney, indicating an established execution channel
• Shares acquired by stock option exercise and paid in cash, clarifying the source of the securities

Negative

• Insider sale of 80,000 shares (aggregate value $97,472) could be perceived negatively by some investors despite its small size

Insights

Securities Analyst

TL;DR: Insider exercise and immediate sale of 80,000 shares valued at $97,472; size is immaterial versus outstanding shares.

The transaction reflects a routine post-exercise disposition routed through a major broker. At 80,000 shares versus 228.36 million outstanding, the sale represents roughly 0.035% of the float, so market impact is negligible. The filing follows Rule 144 disclosure standards and shows no other insider sales in the prior three months, which mitigates concerns about accelerated insider selling pressure. Investors should note the sale date matches the exercise date, indicating liquidity needs or portfolio management rather than staged distribution.

Corporate Governance Expert

TL;DR: Proper disclosure of an option exercise and planned sale; procedural compliance appears intact.

The filer used an established broker and provided required information on acquisition date, payment method, and relationship to the issuer. The signature representation attests no undisclosed material adverse information. These elements suggest compliance with disclosure obligations and internal governance protocols for insider transactions. The scale of the sale is small relative to outstanding shares, limiting governance or control implications.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	80000	97472.00	228356290	09/10/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/10/2025	Stock Option Exercise	Issuer			80000	09/10/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the Form 144 filed by LCTX report?

The filing reports a proposed sale of 80,000 common shares acquired via a stock option exercise and to be sold on 09/10/2025 through Morgan Stanley Smith Barney LLC.

What is the aggregate market value of the shares in the LCTX Form 144?

The aggregate market value reported is $97,472.

How many LCTX shares are outstanding according to the filing?

The filing lists 228,356,290 shares outstanding.

Were there any other sales by the filer in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

How were the acquired LCTX shares paid for?

The filing shows the shares were paid for in cash upon a stock option exercise on 09/10/2025.